System Kosmetik Produktionsgesellschaft fur kosmetische Gmbh
Warning LetterOpen
Ms. Petra Mikschl
Chief Executive Officer/Co-owner
System Kosmetik Produktionsgesellschaft fur kosmetische Gmbh
Raiffeisenstr. 2
Munster
86692 Bavaria
GermanyFEI 3011408975Issued Sep 9, 2022Center for Drug Evaluation and Research | CDER
Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy. To check it, open FDA's record for this establishment, listed under FEI 3011408975.
Violations4
Issue DateSep 9, 2022
Product TypeDrugs
StatusOpen
Letter Details
Firm
System Kosmetik Produktionsgesellschaft fur kosmetische Gmbh
Location
Ms. Petra Mikschl
Chief Executive Officer/Co-owner
System Kosmetik Produktionsgesellschaft fur kosmetische Gmbh
Raiffeisenstr. 2
Munster
86692 Bavaria
Germany
FEI Number
3011408975
Country
Germany
Issue Date
September 09, 2022
Issuing Office
Center for Drug Evaluation and Research | CDER
Product Type
Drugs
Status
Open
Summary
System Kosmetik Produktionsgesellschaft für kosmetische GmbH, a German drug manufacturer, failed to establish adequate written procedures for production, process control, and equipment cleaning/maintenance as required by Current Good Manufacturing Practice (CGMP) regulations. The facility could not provide documentation demonstrating that its over-the-counter drug products were validated to meet predetermined quality requirements consistently and reliably, and lacked qualification protocols, reports, or studies to support product identity, strength, quality, and purity claims. These manufacturing deficiencies rendered the company's drug products adulterated under the Federal Food, Drug, and Cosmetic Act, resulting in significant CGMP violations identified during a February 2022 FDA inspection.
System Kosmetik Produktionsgesellschaft fur kosmetische Gmbh FDA Warning Letter, September 9, 2022